Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Revaprazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 known ✓ | Q9ULD8 | 10/20 | 0.37 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.34 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.34 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Revaprazan SCHEMBL6992634 | 1.00 | LMNA (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL29407864 | 1.00 | LMNA (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL29405266 | 1.00 | LMNA (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL6994677 | 1.00 | LMNA (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL6990999 | 0.99 | MEN1 (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL29388090 | 0.99 | MEN1 (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL2194461 | 0.99 | MEN1 (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL6993033 | 0.99 | MEN1 (0.40) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Revaprazan SCHEMBL1651435 | 0.97 | MEN1 (0.38) | LMNAKDM4EHPGDTSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL6990047 | 0.92 | SMN1; SMN2 (0.40) | LMNAKDM4EHPGDMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3955927-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | Borody, Thomas Julius (AU) | 2022-02-23 | — | — | EP | claimed |
| CN-113939293-A | Compositions and methods for treating, ameliorating and preventing helicobacter pylori infection | 托马斯·朱利叶斯·波洛迪 | 2022-01-14 | — | — | CN | claimed |
| WO-2020210878-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | BORODY THOMAS J (AU) | 2020-10-22 | — | — | WO | claimed |
| EP-0775120-B1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2003-06-04 | — | — | EP | claimed |
| US-5750531-A | ANTISECRETORY AGENTS FOR THE TREATMENT OF PEPTIC ULCER | YUHAN CORPORATION (KR) | 1998-05-12 | — | — | US | claimed |
| EP-0775120-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 1997-05-28 | — | — | EP | claimed |
| WO-1996005177-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1996-02-22 | — | — | WO | claimed |
| CN-115475166-B | Application, medicine and preparation method of revaprazan compound | 中南大学湘雅医院 | 2023-11-21 | — | — | CN | disclosed |
| CN-116492305-A | Loflupridine hydrochloride tablet and preparation method thereof | 郑州大学第一附属医院 | 2023-07-28 | — | — | CN | disclosed |
| CN-115475166-A | Application of revaprazan compound, medicine and preparation method | 中南大学湘雅医院 | 2022-12-16 | — | — | CN | disclosed |
| EP-3955927-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | Borody, Thomas Julius (AU) | 2022-02-23 | — | — | EP | disclosed |
| CN-113939293-A | Compositions and methods for treating, ameliorating and preventing helicobacter pylori infection | 托马斯·朱利叶斯·波洛迪 | 2022-01-14 | — | — | CN | disclosed |
| CN-105919998-B | Acid pump antagonists for the treatment of diseases associated with abnormal gastrointestinal motility | 拉夸里亚创药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| EP-0896580-A1 | SPECIFIC IMMUNOPHILIN LIGANDS AS ANTIASTHMATICS AND IMMUNOSUPPRESSANTS | ASTA Medica Aktiengesellschaft (DE) | 1999-02-17 | — | — | EP | disclosed |
| US-5750531-A | ANTISECRETORY AGENTS FOR THE TREATMENT OF PEPTIC ULCER | YUHAN CORPORATION (KR) | 1998-05-12 | — | — | US | disclosed |
| WO-1998018784-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 1998-05-07 | — | — | WO | disclosed |
| WO-1997042186-A1 | PROCESS FOR PREPARATION OF PYRIMIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997041148-A1 | SPECIFIC IMMUNOPHILIN LIGANDS AS ANTIASTHMATICS AND IMMUNOSUPPRESSANTS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1997-11-06 | — | — | WO | disclosed |
| EP-0775120-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005177-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1996-02-22 | — | — | WO | disclosed |